FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3170331504> ?p ?o ?g. }

• W3170331504 endingPage "1166" @default.
• W3170331504 startingPage "1157" @default.
• W3170331504 abstract "The phase III CHAARTED trial established upfront androgen-deprivation therapy (ADT) plus docetaxel (D) as a standard for metastatic hormone-sensitive prostate cancer (mHSPC) based on meaningful improvement in overall survival (OS). Biological prognostic markers of outcomes and predictors of chemotherapy benefit are undefined.Whole transcriptomic profiling was performed on primary PC tissue obtained from patients enrolled in CHAARTED prior to systemic therapy. We adopted an a priori analytical plan to test defined RNA signatures and their associations with HSPC clinical phenotypes and outcomes. Multivariable analyses (MVAs) were adjusted for age, Eastern Cooperative Oncology Group status, de novo metastasis presentation, volume of disease, and treatment arm. The primary endpoint was OS; the secondary endpoint was time to castration-resistant PC.The analytic cohort of 160 patients demonstrated marked differences in transcriptional profile compared with localized PC, with a predominance of luminal B (50%) and basal (48%) subtypes, lower androgen receptor activity (AR-A), and high Decipher risk disease. Luminal B subtype was associated with poorer prognosis on ADT alone but benefited significantly from ADT + D [OS: hazard ratio (HR) 0.45; P = 0.007], in contrast to basal subtype which showed no OS benefit (HR 0.85; P = 0.58), even in those with high-volume disease. Higher Decipher risk and lower AR-A were significantly associated with poorer OS in MVA. In addition, higher Decipher risk showed greater improvements in OS with ADT + D (HR 0.41; P = 0.015).This study demonstrates the utility of transcriptomic subtyping to guide prognostication in mHSPC and potential selection of patients for chemohormonal therapy, and provides proof of concept for the possibility of biomarker-guided selection of established combination therapies in mHSPC." @default.
• W3170331504 created "2021-06-22" @default.
• W3170331504 creator A5000156180 @default.
• W3170331504 creator A5001783218 @default.
• W3170331504 creator A5002909668 @default.
• W3170331504 creator A5006273748 @default.
• W3170331504 creator A5012825445 @default.
• W3170331504 creator A5014582211 @default.
• W3170331504 creator A5020006331 @default.
• W3170331504 creator A5022442590 @default.
• W3170331504 creator A5028797792 @default.
• W3170331504 creator A5039044023 @default.
• W3170331504 creator A5042227397 @default.
• W3170331504 creator A5070623757 @default.
• W3170331504 creator A5072952875 @default.
• W3170331504 creator A5076238068 @default.
• W3170331504 creator A5088454264 @default.
• W3170331504 creator A5090879940 @default.
• W3170331504 date "2021-09-01" @default.
• W3170331504 modified "2023-10-16" @default.
• W3170331504 title "Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial" @default.
• W3170331504 cites W1508662657 @default.
• W3170331504 cites W1578291413 @default.
• W3170331504 cites W2050146329 @default.
• W3170331504 cites W2078129874 @default.
• W3170331504 cites W2096283457 @default.
• W3170331504 cites W2107633226 @default.
• W3170331504 cites W2132619562 @default.
• W3170331504 cites W2141414987 @default.
• W3170331504 cites W2150865892 @default.
• W3170331504 cites W2161112598 @default.
• W3170331504 cites W2214621962 @default.
• W3170331504 cites W2587831721 @default.
• W3170331504 cites W2601335591 @default.
• W3170331504 cites W2613162682 @default.
• W3170331504 cites W2620706965 @default.
• W3170331504 cites W2620746860 @default.
• W3170331504 cites W2620798309 @default.
• W3170331504 cites W2783798065 @default.
• W3170331504 cites W2787804990 @default.
• W3170331504 cites W2788841415 @default.
• W3170331504 cites W2904249129 @default.
• W3170331504 cites W2906054753 @default.
• W3170331504 cites W2947014957 @default.
• W3170331504 cites W2947893479 @default.
• W3170331504 cites W2973096717 @default.
• W3170331504 cites W3024601170 @default.
• W3170331504 cites W3031849367 @default.
• W3170331504 cites W3045931295 @default.
• W3170331504 cites W4234736740 @default.
• W3170331504 doi "https://doi.org/10.1016/j.annonc.2021.06.003" @default.
• W3170331504 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8463957" @default.
• W3170331504 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34129855" @default.
• W3170331504 hasPublicationYear "2021" @default.
• W3170331504 type Work @default.
• W3170331504 sameAs 3170331504 @default.
• W3170331504 citedByCount "35" @default.
• W3170331504 countsByYear W31703315042021 @default.
• W3170331504 countsByYear W31703315042022 @default.
• W3170331504 countsByYear W31703315042023 @default.
• W3170331504 crossrefType "journal-article" @default.
• W3170331504 hasAuthorship W3170331504A5000156180 @default.
• W3170331504 hasAuthorship W3170331504A5001783218 @default.
• W3170331504 hasAuthorship W3170331504A5002909668 @default.
• W3170331504 hasAuthorship W3170331504A5006273748 @default.
• W3170331504 hasAuthorship W3170331504A5012825445 @default.
• W3170331504 hasAuthorship W3170331504A5014582211 @default.
• W3170331504 hasAuthorship W3170331504A5020006331 @default.
• W3170331504 hasAuthorship W3170331504A5022442590 @default.
• W3170331504 hasAuthorship W3170331504A5028797792 @default.
• W3170331504 hasAuthorship W3170331504A5039044023 @default.
• W3170331504 hasAuthorship W3170331504A5042227397 @default.
• W3170331504 hasAuthorship W3170331504A5070623757 @default.
• W3170331504 hasAuthorship W3170331504A5072952875 @default.
• W3170331504 hasAuthorship W3170331504A5076238068 @default.
• W3170331504 hasAuthorship W3170331504A5088454264 @default.
• W3170331504 hasAuthorship W3170331504A5090879940 @default.
• W3170331504 hasBestOaLocation W31703315041 @default.
• W3170331504 hasConcept C121608353 @default.
• W3170331504 hasConcept C126322002 @default.
• W3170331504 hasConcept C143998085 @default.
• W3170331504 hasConcept C203092338 @default.
• W3170331504 hasConcept C207103383 @default.
• W3170331504 hasConcept C2777899217 @default.
• W3170331504 hasConcept C2780192828 @default.
• W3170331504 hasConcept C2780275930 @default.
• W3170331504 hasConcept C2781190966 @default.
• W3170331504 hasConcept C44249647 @default.
• W3170331504 hasConcept C530470458 @default.
• W3170331504 hasConcept C535046627 @default.
• W3170331504 hasConcept C71924100 @default.
• W3170331504 hasConceptScore W3170331504C121608353 @default.
• W3170331504 hasConceptScore W3170331504C126322002 @default.
• W3170331504 hasConceptScore W3170331504C143998085 @default.
• W3170331504 hasConceptScore W3170331504C203092338 @default.
• W3170331504 hasConceptScore W3170331504C207103383 @default.
• W3170331504 hasConceptScore W3170331504C2777899217 @default.
• W3170331504 hasConceptScore W3170331504C2780192828 @default.

• next